Introduction
Hypercholesterolemia is a disorder of the metabolism of dietary fats that affects approximately 31.7% of the total US population and results in great health care costs (1, 2) . Elevated cholesterol levels are a well-defined risk factor for cardiovascular diseases (CVD) and stroke.
Mevalonate, an important metabolite involved in cholesterol biosynthesis, is catalyzed by 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (EC 1.1.1.34). Because over 70% of the total body cholesterol is produced by de novo biosynthesis (3), inhibition of this enzyme can be a way to regulate fat metabolism because it will result in a significant reduction of blood cholesterol after consumption of a mixed fat diet. Therefore, HMG-CoA reductase inhibitors are widely prescribed to decrease blood cholesterol levels in humans and animals and are well documented (4) .
Policosanol, a long-chain aliphatic alcohol (C26-C32) isolated from wax of sugar cane (Saccharum officinarum L.), was shown to decrease blood cholesterol levels in human and animal trials (5, 6) . Policosanol supplements have been approved as a cholesterol-lowering supplement in over 25 countries (7) . Previous studies have demonstrated that policosanol could lower blood cholesterol via the promotion of AMPkinase phosphorylation and HMG-CoA reductase in the liver of mice and hepatoma cells following intragastric administration (8, 9) . This phosphorylation decreases HMG-CoA reductase activity about 70-80% (9) . Similar results indicating that policosanol treatments decrease hepatic cholesterol synthesis in rabbits and rats models have been reported (6, 10, 11) . These results provide a solid biochemical mode of action to prove the ability of policosanol to lower cholesterol biosynthesis via the inhibition of HMG-CoA reductase and subsequent activation of AMP-kinase (8, 9, 12) .
Activation of AMP-kinase is very important for the signaling of insulin, the body energy balance, and the metabolism of dietary glucose and fats (13, 14) . Metformin, one of the drugs for diabetes mellitus, is reported to decrease cholesterol/glucose levels via activation of AMP-activated protein kinase (AMPK) (15, 16) . Interestingly, policosanol has also been shown to increase the phosphorylation of the principal AMPK, liver kinase B1 (LKB1), and this increase was slightly less than the increase caused by metformin (9) . Additionally, the activation of AMPK through the use of long chain fatty acids has been demonstrated (17) . Taken together, it is possible to manage both blood glucose and cholesterol levels using policosanol via AMPkinase activation processes.
Therefore, in this study, the effect of supplementation of policosanol on the blood cholesterol and glucose management was evaluated using Wistar rats fed a high cholesterol diet. Policosanol was administrated for 42 days in Wistar rats. The effects of policosanol supplementation were compared with lovastatin, a HMG-CoA reductase inhibitor. Changes in blood glucose levels, total cholesterol, triglyceride contents, high density lipoprotein (HDL)-cholesterol, low density lipoprotein (LDL)-cholesterol, as well as HMG-CoA reductase activity were investigated. Animal and study design Wistar rats (5-week-old male) were obtained from Joongang Experimental Animal Co. (Seoul, Korea). Purina Pico #5053 diet (Oriental Bio. Co., Seongnam, Korea) was fed to all rats for one week. After 1 week, the diet was switched to the high-cholesterol diet D12336 (Raon Bio Inc.) for another 6 weeks. During the high-cholesterol diet D12336 administration for 6 weeks, policosanol and lovastatin were administered once a day (9-10 AM).
Materials and Methods
Policosanol was suspended in a Tween 20-water vehicle (0.4% Tween 20 solution) and orally administered by gastric gavage (1 mL/kg). Three groups were used: a control group receiving the vehicle, and two treated groups receiving 0.008 and 0.006 g of policosanol and lovastatin/kg/day, respectively. Wistar male rats were single-housed in stainless cages with a 12 h light and dark cycle. The animal laboratory was maintained with 50±8% relative humidity. The number of Wistar rat in each group was 10. The experimental protocols were evaluated and approved by the Hannam University Institutional Animal Care and Use Committee (HNU-IACUC) (Approval number: HNU2015-0004). The rats were anesthetized with pentobarbital and killed, and then blood samples were obtained.
Blood analysis The glucose level in blood was measured with a glucose analyzer (CaresensII; I-SENS Inc.) by the glucose oxidase method. The assay protocols for total glyceride, total cholesterol, and HDL/LDL-cholesterol concentration in blood followed the method of Menedez et al. (6) using commercial kits (Liquicolor ® test series;
Stanbio Laboratory) and a semi-auto biochemistry analyzer (A6; Beijing Shinging Sun Technology Co., Ltd., Beijing, China).
HMG-CoA reductase activity The preparation of microsomes from rats' livers and the slow freeze-thaw procedure used to solubilize the enzyme have been previously described by Renu and Shrewsbury (18) . Buffer A, which contained 0.2 M sucrose/0.05 M KCl/50 mM phosphate buffer (pH 7.0)/0.03 M EDTA, was used for the preparation of microsomes and Buffer B (Buffer A containing 10 rnM dithiothreitol) was used for the preparation of solubilized enzyme and in the subsequent purification. Briefly, the frozen microsomes were thawed at room temperature and gently homogenized with ground glass Potter-Elvehjem type glass homogenizers (Sigma-P7859; SigmaAldrich Co., St. Louis, MO, USA) in ice-cold Buffer B in a total volume of 240 mL. The homogenate was centrifuged at 105,000×g for 1 h and the supernatant referred to as Fraction I was collected. A repeat of the freezing-thawing homogenization procedure in a total volume of 120 mL and centrifugation gave the Fraction II supernatant. Both Fractions I and II were then combined and incubated at 37 o C for 3 h. During this treatment, the solution became turbid and the insoluble components were removed by centrifugation at 34,000× g for 10 min. The clear supernatant that contained all the enzyme activity was harvested then used for further steps. The hepatic microsomal HMG-CoA reductase activity was measured using a kit (K588-100; BioVison Inc.).
Statistical analysis Results were presented as mean and standard deviation (mean±SD). Statistical analyses were performed by the statistical package "Statistical Package for Social Science (SPSS) ver. 10" (SPSS Inc., Chicago, IL, USA) program. Statistical significance of the data was tested by the Student's t-test and was defined as p<0.05.
Results and Discussion
Effect of policosanol on body weight Effects of policosanol supplementation were investigated in Wistar male rats for 42 days. The body weight in the policosanol-treated group was decreased significantly (p<0.05) compared with the lovastatin treatment and control groups after 42 days (Fig. 1) . These significant changes in body weight between control and treatment groups (policosanol) were shown after 16 days of supplementation (Fig. 1) . The positive control group treated by lovastatin and control group showed similar changes in food consumption while food intake was slightly decreased in the group treated by policosanol (Fig. 2) .
Effects of policosanol supplementation on blood glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglyceride content The effects of treatment with policosanol for 42 days on blood glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride content, and liver/kidney weights were also investigated as shown in Table 1 and Fig. 3 . Glucose levels in blood were Fig. 2 . Changes in food intake after the administration of policosanol. Five-week-old male Wistar rats were fed a normal diet (Pico 5053) for 1 week. After 1 week, the diet was switched to a high-cholesterol diet (D12336) for another 6 weeks. During the high-cholesterol diet administration for 6 weeks, policosanol and lovastatin were administered once a day (9-10 AM). Policosanol was suspended in a Tween 20-water vehicle (0.4% Tween 20 solution) and was orally administered by gastric gavage (1 mL/kg). Three groups were used: a control group receiving the vehicle, and two treated groups receiving 0.008 and 0.006 g of policosanol and lovastatin/kg/day, respectively. Each point represents mean±standard deviation (SD) (n=10). Body weight levels were compared between control and treatment groups at each time point by unpaired Student's t-test (*p<0.05). Fig. 1 . Changes in body weight after administration of policosanol. Five-week-old male Wistar rats were fed a normal diet (Pico 5053) for 1 week. After 1 week, the diet was switched to a high-cholesterol diet (D12336) for another 6 weeks. During the high-cholesterol diet administration for 6 weeks, policosanol and lovastatin were administered once a day (9-10 AM). Policosanol was suspended in a Tween 20-water vehicle (0.4% Tween 20 solution) and was orally administered by gastric gavage (1 mL/kg). Three groups were used: a control group receiving the vehicle, and two treated groups receiving 0.008 and 0.006 g of policosanol and lovastatin/kg/day, respectively. Each point represents mean±standard deviation (SD) (n=10). Body weight levels were compared between control and treatment groups at each time point by unpaired Student's t-test (*p<0.05).
significantly decreased in the policosanol treatment group (p<0.01) similarly to the lovastatin treatment group (p<0.001) ( Table 1 and Fig.  3 ). In the control group, the average glucose level in blood was 161.1 (mg/dL). Blood glucose levels in the policosanol and lovastatin groups were 148.2 (mg/dL) and 147.5 (mg/dL), respectively (Table 1) . While total cholesterol level in the control group was 204.9 (mg/dL), the total cholesterol levels in the policosanol (p<0.01) and lovastatin treatment groups were 166.0 and 173.9 mg/dL, respectively (Table  1) . Serum triglyceride levels of groups who were administered either policosanol or lovastatin were found to be not significantly different from each other ( Table 1) . HDL-cholesterol showed a tendency to increase with both policosanol and lovastatin supplementation; however, this finding was not statistically significant (Table 1) . LDLcholesterol, which is known to be associated with atherosclerosis and CVD, was significantly decreased in both policosanol (p<0.01) and lovastatin (p<0.01) treatment groups. Several in vivo studies showed that policosanol consumption has blood LDL-cholesterol lowering effects in in vivo studies (19) and in human clinical studies (20) . Similar results have been reported suggesting that policosanol treatments decrease blood LDL-cholesterol levels in human clinical trials (21, 22) . Yanai et al. reported that policosanol had a LDLcholesterol lowering effect (7).
Our findings indicate that policosanol could prevent body weight gain and cholesterol content induced by a cholesterol-enriched diet in a similar manner to the HMG-CoA reductase inhibitor, lovastatin ( Fig. 1 and Table 1 ). However, recent studies have indicated that policosanol could not inhibit HMG-CoA reductase directly (9) . Therefore, the HMG-CoA reductase-lowering effect seen in the Each point represents mean±SD (n=10). All parameters were compared between control and treatment groups at 42 day by unpaired Student's t-test (*p<0.05; **p<0.01; and ***p<0.001).
Fig. 3.
Changes in blood glucose level after administration of policosanol. Five-week-old male Wistar rats were fed a normal diet (Pico 5053) for 1 week. After 1 week, the diet was switched to a high-cholesterol diet (D12336) for another 6 weeks. During the high-cholesterol diet (D12336) administration for 6 weeks, policosanol and lovastatin were administered once a day (9-10 AM). Policosanol was suspended in a Tween 20-water vehicle (0.4% Tween 20 solution) and was orally administered by gastric gavage (1 mL/kg). Three groups were used: a control group receiving the vehicle, and two treated groups receiving 0.008 and 0.006 g of policosanol and lovastatin/kg/day, respectively. Each point represents mean±standard deviation (SD) (n=10). Body weight levels were compared between control and treatment groups at each time point by unpaired Student's t-test (*p<0.05).
present study might be linked to HMG-CoA reductase activity, one of the key enzymes in cholesterol synthesis (9) . Further specific enzyme activity assays and protein expression will be implemented to confirm the mechanism of action.
Changes in HMG-CoA reductase activity and liver/kidney weights HMG-CoA reductase is one of the rate-controlling enzymes in the mevalonate pathway that produces cholesterol from acetyl-CoA. In an NADPH-dependent reaction, HMG-CoA reductase reduces HMGCoA to generate mevalonate and CoA. The enzyme is the target of a group of cholesterol-lowering drugs known as statins. Inhibition of HMG-CoA reductase induces expression of LDL receptors in the liver, which lowers plasma concentrations of cholesterol. Therefore, hepatic HMG-CoA reductase activity was evaluated after biopsy in all groups in the current study. The policosanol treatment group had the lowest activity (0.017 units/mg protein), followed by the lovastatin treatment group (0.023 units/mg protein), while the control group had the highest HMG-CoA reductase activity (0.028 units/mg protein) ( Table 1 ). In order to evaluate the side effects of these 2 samples, liver and kidney weights were also measured after biopsy and control, policosanol, and lovastatin treatment groups had no significant differences in liver and kidney weights (Table 1 ). Our findings suggest that, in an animal model, policosanol has an suppressive effect against cholesterol production due to inhibition of HMG-CoA reductase. Although several in vivo studies (19) as well as human clinical studies (8, 21, 22) have shown that policosanol consumption has a blood LDL-cholesterol lowering effect, we must not overlook other clinical reports in patients with hypercholesterolemia or combined hyperlipidemia that have shown that policosanol had no effect (23, 24) . Chen et al. (25) performed a systematic review and reported that policosanol induced a clinically significant decrease in the LDL/ HDL ratio (4,596 patients from 52 clinical studies). This could be due to the fact that policosanol has different alcohols profiles which could result in different functionalities. Our future research will include the evaluation of individual alcohols contained within policosanol to identify the most bioactive alcohol. For the generation of consistent results, bioactivity-based standardization of the policosanol alcohol profile is essential.
Epidemiological studies suggest that policosanol supplementation can reduce the blood cholesterol levels in human clinical studies (26, 27) . Activation of AMP-kinase plays an important role in insulin signaling, whole body energy balance, and the metabolism of glucose and fats (13, 14) . The principal AMP-kinase, liver kinase B1 (LKB1) phosphorylation was increased 3-fold in hepatoma cells by policosanol, slightly less than that seen with metformin, a known activator of LKB1 (9) . In this study, glucose levels in blood were significantly decreased in the policosanol treatment group (p<0.01) similarly to the lovastatin treatment group (p<0.001) ( Table 1 and Fig. 3 ). These results indicate that it is possible to manage both blood glucose and cholesterol levels using policosanol via an AMP-kinase activation process. Although a large part of this effect is attributed to the ability of policosanol to increase AMP-kinase phosphorylation and inhibit HMG-CoA reductase, the indirect potential of policosanol on blood glucose lowering cannot be excluded and is an interesting idea for further studies.
Policosanol and/or policosanol metabolites may inhibit cholesterol absorption across intestinal cells by partially oxidizing cholesterol ester fatty acids (28) or policosanol-increased bile acid excretion as shown previously (29) . This will lower the blood cholesterol level by making the liver utilize cholesterol to synthesize more bile. Although we did not measure lipid content or bile acids in fecal matter, we found oily fecal matter in the rat cage changing pads during the study. Therefore, based on this possibility, fecal analysis should be performed in our follow up study, including measurement of cholesterol, bile acids, and composition etc.
We believe that this manuscript provides a preliminary rationale for how policosanol might inhibit enzymes in the pathway of cholesterol and glucose metabolism. In this study, we report that policosanol can control blood cholesterol, blood glucose, total cholesterol, triglyceride, LDL-cholesterol, and total body weight in a Wistar rat model in a similar manner to lovastatin. Our findings suggest rationale for the deeper evaluation of policosanol and the determination of the most bioactive alcohols for the observed bioactivity.
